(Q24235761)

English

Combination inhaled steroid and long-acting beta(2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease

scientific article

In more languages

Statements

scholarly article

0 references

0 references

1 reference

Europe PubMed Central

Combination inhaled steroid and long-acting beta(2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease (English)

0 references

chronic obstructive pulmonary disease

0 references

author name string

Charlotta Karner

1

author given names

Charlotta

author last names

Karner

1 reference

PubMed publication ID

19 October 2023

Christopher J Cates

2

author given names

Christopher J

author last names

Cates

1 reference

PubMed publication ID

19 October 2023

language of work or name

0 references

publication date

2011

0 references

Cochrane Database of Systematic Reviews

0 references

3

0 references

CD008532

0 references

Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170905

19 March 2017

Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170905

19 March 2017

Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170905

19 March 2017

Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170905

19 March 2017

Self-management education for patients with chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170905

19 March 2017

Inhaled corticosteroids for stable chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170905

19 March 2017

Pulmonary rehabilitation for chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170905

19 March 2017

Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170905

19 March 2017

Tiotropium for stable chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170905

19 March 2017

The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170905

27 September 2017

Outcomes for COPD pharmacological trials: from lung function to biomarkers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170905

27 September 2017

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170905

30 May 2018

The Canadian Optimal Therapy of COPD Trial: design, organization and patient recruitment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008532.PUB2

21 January 2018

Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008532.PUB2

21 January 2018

Tiotropium and salmeterol/fluticasone combination do not cause oxygen desaturation in COPD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008532.PUB2

21 January 2018

Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008532.PUB2

21 January 2018

Acute care costs of patients admitted for management of chronic obstructive pulmonary disease exacerbations: contribution of disease severity, infection and chronic heart failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008532.PUB2

21 January 2018

Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008532.PUB2

21 January 2018

Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170905

29 November 2018

Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170905

29 November 2018

Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170905

29 November 2018

Additive benefits of tiotropium in COPD patients treated with long-acting beta agonists and corticosteroids.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170905

29 November 2018

A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4170905

29 November 2018

Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008532.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/14651858.CD008532.PUB2

0 references

release_ug6nprthy5dk5b7ouza6qztj6u

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24235761&oldid=1993594678"